Research programme: cardiovascular disease therapeutics - Eli Lilly/Zydus Cadila
Latest Information Update: 16 Jul 2016
At a glance
- Originator Eli Lilly; Zydus Cadila
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in India
- 16 Apr 2010 Early research in Cardiovascular disorders in India (unspecified route)